Stability and prognostic value of Slug, Sox9 and Sox10 expression in breast cancers treated with neoadjuvant chemotherapy

SpringerPlus

Volumn 2, Issue 1, 2013, Pages

  Riemenschnitter, Cosima ^a   Teleki, Ivett ^b   Tischler, Verena ^a   Guo, Wenjun ^c   Varga, Zsuzsanna ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; Prognosis; Stability; Stem cells; Transcription factors

Indexed keywords

EID: 84891389727     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-695     Document Type: Article

References (27)

1. Ablett M.P., Singh JK, Clarke RB (2012) Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer 48:2104-2116, doi: 10.1016/j.ejca.2012.03.019S0959-8049(12)00303-6 [pii]
2. Chakravarty G., Moroz K, Makridakis NM, Lloyd SA, Galvez SE, Canavello PR, Lacey MR, Agrawal K., Mondal D (2011) Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med (Maywood) 236:145-155, doi: 10.1258/ebm.2010.010086236/2/145 [pii]
3. Chen J.H., Pan WF, Kao J, Lu J, Chen LK, Kuo CC, Chang CK, Chen WP, McLaren CE, Bahri S., Mehta RS, Su MY (2013) Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR. NMR Biomed 26:1705-1713, doi: 10.1002/nbm.3006
4. Cimino-Mathews A, Subhawong AP, Elwood H, Warzecha HN, Sharma R, Park BH, Taube JM, Illei PB, Argani P (2013) Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol 44:959-965, doi: 10.1016/j.humpath.2012.09.005S0046-8177(12)00333-4 [pii]
5. Denkert C., Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R., Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M., von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, doi: 10.1200/JCO.2009.23.7370JCO.2009.23.7370 [pii]
6. Giordano A., Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM (2012) Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 11:2526-2534, doi: 10.1158/1535-7163.MCT-12-0460
7. Guo W., Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-Hardi U, Bell G, Tam WL, Mani SA, van Oudenaarden A, Weinberg RA (2012) Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148:1015-1028, doi: 10.1016/j.cell.2012.02.008S0092-8674(12)00165-1 [pii]
8. Hammond M.E., Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G., Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K., Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S., Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, doi: 10.1200/JCO.2009.25.6529JCO.2009.25.6529 [pii]
9. Ivanov S.V., Panaccione A, Nonaka D, Prasad ML, Boyd KL, Brown B, Guo Y, Sewell A, Yarbrough WG (2013) Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br J Cancer 109:444-451, doi: 10.1038/bjc.2013.326bjc2013326 [pii]
10. Kononen J., Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M.J., Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847
11. Lebeau A., Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U (2001) Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354-363
12. Lips E.H., Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J (2013) Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 140:63-71, doi: 10.1007/s10549-013-2620-0
13. Markiewicz A., Ahrends T, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Jaskiewicz J, Szade J, Biernat W, Zaczek AJ (2012) Expression of epithelial to mesenchymal transitionrelated markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med 10:226, doi: 10.1186/1479-5876-10-2261479-5876-10-226 [pii]
14. Mego M., Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi G.N., Cristofanilli M, Lucci A, Reuben JM (2012) Expression of epithelialmesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer 130:808-816, doi: 10.1002/ijc.26037
15. Mohamed A., Gonzalez RS, Lawson D, Wang J, Cohen C (2013) SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol 21:506-510, doi: 10.1097/PAI.0b013e318279bc0a
16. Muller P., Crofts JD, Newman BS, Bridgewater LC, Lin CY, Gustafsson JA, Strom A (2010) SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells. Breast Cancer Res Treat 120:317-326, doi: 10.1007/s10549-009-0381-6
17. Payne S.J., Bowen RL, Jones JL, Wells CA (2008) Predictive markers in breast cancer-the present. Histopathology 52:82-90, doi: 10.1111/j.1365-2559.2007.02897.xHIS2897 [pii]
18. Shin J., Vincent JG, Cuda JD, Xu H, Kang S, Kim J, Taube JM (2012) Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. J Am Acad Dermatol 67:717-726, doi: 10.1016/j.jaad.2011.12.035S0190-9622(12)00013-8 [pii]
19. Smalley M., Piggott L, Clarkson R (2013) Breast cancer stem cells: obstacles to therapy. Cancer Lett 338:57-62, doi: 10.1016/j.canlet.2012.04.023S0304-3835(12)00271-6 [pii]
20. Soady K., Smalley MJ (2012) Slugging their way to immortality: driving mammary epithelial cells into a stem cell-like state. Breast Cancer Res 14:319, doi: bcr3188 [pii]10.1186/bcr3188
21. Symmans W.F., Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B., Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, doi: 10.1200/JCO.2007.10.6823
22. Teleki I., Krenacs T, Szasz MA, Kulka J, Wichmann B, Leo C, Papassotiropoulos B, Riemenschnitter C., Moch H, Varga Z (2013) The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer. BMC Cancer 13:50, doi: 10.1186/1471-2407-13-50
23. Theurillat J.P., Zurrer-Hardi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D., Ferrone S, Pestalozzi B, Jungbluth AA, Chen YT, Jager D, Knuth A, Moch H (2007) NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 56:1723-1731, doi: 10.1007/s00262-007-0316-1
24. van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, Smit VT, Liefers GJ, Kuppen P.J., van de Velde CJ, Bartlett JM (2012) Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 133:49-59, doi: 10.1007/s10549-011-1684-y
25. Varga Z., Caduff R, Pestalozzi B (2005) Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 446:136-141, doi: 10.1007/s00428-004-1164-4
26. Wolff A.C., Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons P.L., Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
27. Yoshioka T., Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y., Yamashita H (2013) Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer, doi: 10.1007/s12282-013-0474-2